Skip to main content

Advertisement

Table 3 End-stage renal disease and albuminuria associations with p.R229Q in different diabetic cohorts

From: NPHS2variation in focal and segmental glomerulosclerosis

  N = 280 Type I (n = 41) Type 2 (n = 239) Total (n = 280)
Utah diabetes study No ESRD
(n = 171)
21 p.R229R 0 p.R229Q 140 p.R229R 10 p.R229Q 161 p.R229R 10 p.R229Q
  ESRD
(n = 109)
17 p.R229R 3 p.R229Q
2 3.40, p = 0.07)
82 p.R229R 7 p.R229Q (2%)
2 0.12, p = 0.73)
99 p.R229R 10 p.R229Q (2%)
2 1.11, p = 0.29)
  N = 1,279 Type I (n = 1,279) Type 2 - Total -
GoKinD No ESRD
(n = 824)
759 p.R229R 65 p.R229Q - - - -
  ESRD
(n = 455)
428 p.R229R p.27 R229Q
2 1.68, p = 0.20)
- - - -
  N = 429 Type I (n = 67) Type 2 (n = 357) Total (n = 429)
Australian endocrine Normo
(n = 279)
47 p.R229R 4 p.R229Q 206 p.R229R 22 p.R229Q 253 p.R229R 26 p.R229Q
  Micro
(n = 93)
8 p.R229R 2 p.R229Q
2 1.39, p = 0.24)
77 p.R229R 6 p.R229Q (2%)
2 0.44, p = 0.51)
85 p.R229R 8 p.R229Q (2%)
2 0.04, p = 0.84)
  Macro
(n = 52)
6 p.R229R 0 p.R229Q
2 0.5, p = 0.48)
42 p.R229R 4 p.R229Q (2%)
2 0.04, p = 0.84)
48 p.R229R 4 p.R229Q (2%)
2 0.14, p = 0.71)
  Micro- or Macro
(n = 145)
14 p.R229R 2 p.R229Q
2 0.32, p = 0.57)
119 p.R229R 10 p.R229Q (2%)
2 0.36, p = 0.55)
133 p.R229R 12 p.R229Q (2%)
2 0.13, p = 0.72)
  1. The frequency of p.R229Q in patients with type 1 or type 2 diabetes with end-stage renal disease (ESRD) was compared to those without for the Utah diabetes study and Genetics of Kidney Disease in Diabetes (GoKinD) participants. Likewise, the frequency of p.R229Q in patients with microalbuminuria (Micro) or macroalbuminuria (Macro) was compared with the frequency of normoalbuminuria (Normo) in patients with type 1 or type 2 diabetes in the Australian endocrine patients. No associations were found.